 |
|
VIGNETTES
Efficacy of Treatment With Tetracyclines to Prevent Acneiform Eruption Secondary to Cetuximab Therapy
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In the last few years, several clinical trials have demonstrated the efficacy of cetuximab, a chimeric IgG1 monoclonal antibody that binds to the epidermal growth factor receptor, in the treatment of metastatic colorectal cancer.1-2 The most frequent cutaneous adverse effect of cetuximab therapy is an acneiform eruption, observed in approximately 90% of patients within 1 to 3 weeks after therapy initiation.1-5
Several treatments, including topical applications of triamcinolone acetonide, betamethasone dipropionate, benzoyl peroxide, nystatin, ketoconazole, econazole, and topical (erythromycin, fusidic acid, and clindamycin) and systemic (fusidic acid and minocycline) antibiotics, have been used to treat cetuximab-associated acneiform eruption with only partial improvement or no response.1-4 In a recent study,5 preventive treatment with systemic fusidic acid and topical 4% erythromycin emulsion decreased the acneiform eruptions considerably, with the only cutaneous adverse effect being erythema in the absence of papular or pustular follicular lesions.
We report the success of a prophylactic treatment . . . [Full Text of this Article] Report of a Case
Comment
AUTHOR INFORMATION
Tamara Micantonio, MD;
Maria Concetta Fargnoli, MD;
Enrico Ricevuto, MD;
Corrado Ficorella, MD;
Paolo Marchetti, MD;
Ketty Peris, MD
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Randomized Double-Blind Trial of Prophylactic Oral Minocycline and Topical Tazarotene for Cetuximab-Associated Acne-Like Eruption
Scope et al.
JCO 2007;25:5390-5396.
ABSTRACT
| FULL TEXT
Epidermal Growth Factor Receptor Inhibitor-Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management
Lynch et al.
The Oncologist 2007;12:610-621.
ABSTRACT
| FULL TEXT
|
